Exploiting RIG-I-like receptor pathway for cancer immunotherapy

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• RIG-I-like receptors (RLRs) are crucial pattern recognition receptors sensing pathogen-associated molecular patterns (PAMPs) and endogenous danger signals.
• Dysregulation of RLRs signaling is implicated in infections, immune deficiencies, and cancer development.
• RLRs family members, including RIG-I, MDA5, and LGP2, possess distinct RNA recognition and signaling capabilities.

Purpose of the Study:

• To review current knowledge on RLRs signaling pathways.
• To discuss the therapeutic potential of targeting RLRs in cancer treatment.
• To explore novel strategies for RLRs activation and their integration with existing cancer therapies.

Main Methods:

• Literature review of RLRs signaling mechanisms and therapeutic applications.
• Analysis of RLRs activation by various stimuli, including synthetic RNAs and oncolytic viruses.
• Examination of clinical trial data for RLRs-based cancer therapies.

Main Results:

• RLRs recognize diverse RNA ligands, including viral, bacterial, and endogenous RNAs.
• Therapeutic RLRs activation can induce anti-infection immunity and anti-tumor responses.
• Strategies for in vivo delivery of RLRs agonists and combination therapies are emerging.

Conclusions:

• Targeting RLRs represents a promising strategy for developing novel anti-infective and anti-cancer therapeutics.
• Integration of RLRs agonism with RNA interference or CAR-T cells offers synergistic effects in cancer immunotherapy.
• Further elucidation of RLRs signaling mechanisms is essential for advancing cancer therapeutics and immunotherapy.